Literature DB >> 8608408

Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells.

G Chen1, K J Hutter, W J Zeller.   

Abstract

While multiple changes are frequently found to be associated with cisplatin resistance in a variety of tumor cell lines, a cause-effect relationship of these alterations with the resistant phenotype has not been established. In order to identify the resistance-relevant determinants, a series of cisplatin-resistant sublines with different degrees of resistance to cisplatin was developed in a human ovarian carcinoma cell line (O-129). Three derived resistant cell lines displayed 2.1-fold (O-129/DDP4, low), 4.1-fold (O-129/DDP8, moderate) and 6.3-fold (O-129/DDP16, high) resistance, respectively, to cisplatin, compared with the sensitive parental line O-129. While the activity of poly(ADP-ribose) polymerase, an enzyme proposed to be involved in DNA repair, was elevated in all three resistant lines, a significant karyotypic change was observed only in the high-resistance line with the karyotype alteration from near diploidy to heteroploidy. The moderate (4.1-fold) and high (6.3-fold) DDP resistance was associated with a slow proliferation rate in drug-free medium, but cellular glutathione level was highly correlated with DDP sensitivity in all four cell lines. Taken together, the present studies establish that while many changes at cellular level can occur with development of cisplatin resistance, only elevation of intracellular glutathione concentration appears to be related to the resistance phenotype in these human ovarian cancer cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8608408     DOI: 10.1007/bf00757625

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  27 in total

1.  In vitro investigations on induction and reversal of cisplatin resistance in a rat ovarian tumor cell line.

Authors:  G Chen; W J Zeller
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  Karyotypic change from heteroploidy to near diploidy associated with development of cisplatin resistance in a rat ovarian tumour cell line.

Authors:  G Chen; K J Hutter; J Bullerdiek; W J Zeller
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  Karyotyping.

Authors:  R G Worton; C Duff
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

4.  Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine.

Authors:  O W Griffith
Journal:  Anal Biochem       Date:  1980-07-15       Impact factor: 3.365

Review 5.  Resistance to cisplatin and analogues: mechanisms and potential clinical implications.

Authors:  A de Graeff; R J Slebos; S Rodenhuis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  Inhibition of poly(ADP-ribose) polymerization preserves the glutathione pool and reverses cytotoxicity in hydrogen peroxide-treated lymphocytes.

Authors:  M Marini; F Frabetti; M A Brunelli; M A Raggi
Journal:  Biochem Pharmacol       Date:  1993-12-14       Impact factor: 5.858

7.  Increased poly(ADP-ribose) formation in cisplatin-resistant rat ovarian tumor cells.

Authors:  G Chen; W J Zeller
Journal:  Anticancer Res       Date:  1994 Jul-Aug       Impact factor: 2.480

8.  Tumor heterogeneity and drug resistance.

Authors:  D L Dexter; J T Leith
Journal:  J Clin Oncol       Date:  1986-02       Impact factor: 44.544

9.  Cell culture of tumors alters endogenous poly(ADPR)polymerase expression and activity.

Authors:  M G Chabert; P C Kopp; P L Bischoff; P Mandel
Journal:  Int J Cancer       Date:  1993-03-12       Impact factor: 7.396

Review 10.  Modulation of cis-diamminedichloroplatinum(II) resistance: a review.

Authors:  H Timmer-Bosscha; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

View more
  7 in total

Review 1.  Clinical perspectives on platinum resistance.

Authors:  G Giaccone
Journal:  Drugs       Date:  2000       Impact factor: 9.546

2.  PITPNA-AS1/miR-98-5p to Mediate the Cisplatin Resistance of Gastric Cancer.

Authors:  Zhongling Ma; Gang Liu; Suhong Hao; Tianfu Zhao; Wei Chang; Jiansheng Wang; Hong Ren; Xinhan Zhao
Journal:  J Oncol       Date:  2022-05-07       Impact factor: 4.501

3.  Insight into the toxic effects of cis-dichloridoplatinum(II) complexes containing 7-azaindole halogeno derivatives in tumor cells.

Authors:  Tereza Muchova; Jitka Pracharova; Pavel Starha; Radana Olivova; Oldrich Vrana; Barbora Benesova; Jana Kasparkova; Zdenek Travnicek; Viktor Brabec
Journal:  J Biol Inorg Chem       Date:  2013-05-15       Impact factor: 3.358

4.  Cisplatin nephrotoxicity: molecular mechanisms.

Authors:  Marie H Hanigan; Prasad Devarajan
Journal:  Cancer Ther       Date:  2003

5.  Lipid peroxidative damage on Cisplatin exposure and alterations in antioxidant defense system in rat kidneys: a possible protective effect of selenium.

Authors:  Branka I Ognjanović; Nataša Z Djordjević; Miloš M Matić; Jasmina M Obradović; Jelena M Mladenović; Andraš Š Štajn; Zorica S Saičić
Journal:  Int J Mol Sci       Date:  2012-02-08       Impact factor: 6.208

6.  Protective effects of N-acetylcysteine on cisplatin-induced oxidative stress and DNA damage in HepG2 cells.

Authors:  Fugen Wang; Shourong Liu; Yiqin Shen; Rangxiao Zhuang; Jianjun Xi; Hongying Fang; Xuwan Pan; Jingjing Sun; Zhaobin Cai
Journal:  Exp Ther Med       Date:  2014-10-13       Impact factor: 2.447

7.  Theaflavin-3,3'-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells.

Authors:  Haibo Pan; Eunhye Kim; Gary O Rankin; Yon Rojanasakul; Youying Tu; Yi Charlie Chen
Journal:  Int J Mol Sci       Date:  2018-01-02       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.